AstraZeneca PLC (AZN) Income Statement
An income statement shows a company's revenue, expenses, and profit over a reporting period.
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
Total Revenue Chart for AstraZeneca PLC
AstraZeneca PLC (AZN) revenue for FY2025 was GBP 58.7B, a 10.9% change from FY2024. AstraZeneca PLC's revenue grew from GBP 7.3B in 1990 to GBP 58.7B in 2025 (699.3% over 35 years). Earnings per share grew from GBP 1.44 in 2000 to GBP 2.11 in 2022 (46.8%). Revenue compound annual growth rate: 5-year CAGR of 14.9%, 10-year CAGR of 9.4%, 20-year CAGR of 4.9%.
Total Revenue (British Pounds)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- £216.51B
- Implied Share Price
- £139.60
- Enterprise Value
- £235.96B
- Revenue (TTM)
- £62.38B
- EBITDA
- £21.28B
- Profit Margin
- 17.68%
- Trailing P/E
- 27.98
- Forward P/E
- 16.31
- Price/Book (MRQ)
- 5.60
- Price/Sales (TTM)
- 3.47
- EV/EBITDA
- 14.91
- EV/Revenue
- 5.06
- Dividend Yield
- 2.47%
- Book Value
- £24.21
- Free Cash Flow (FY2025)
- £8.67B
- Free Cash Flow Yield
- 4.00%
Snapshot as of 31st October 2026 — not point-in-time controlled, may lag the live market by a few days.